BUZZ - Bristol-Myers Squibb discloses patient death in early autoimmune disease clinical trial; stock price drops
路透社2026/10/23 15:22October 23 - ** Bristol Myers Squibb (BMY.N) shares fell 2.4%, closing at $61.47
** The company stated that after the data cutoff in an early-stage clinical trial, a patient experienced a fatal case of septic pneumonia.
** The company is testing its experimental cancer therapy, zolacabtagene autoleucel, in patients with highly active relapsing multiple sclerosis.
** Multiple sclerosis is an autoimmune disease that affects the central nervous system.
** The company said the trial enrolled a total of 66 patients, and the safety profile of the therapy was consistent with previously reported data.
** Including intraday fluctuations, the stock has risen 13.9% so far this year.
(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses arising from the use of this automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Executives reveal new monetization strategy for Meta AI: Muse is ad-free but charges for enterprise services, and takes a commission on shopping through AI agents
Meta AI chief Alexandr Wang stated that Muse is available to regular users for free and that Meta has no plans to introduce advertisements. Meta plans to offer paid services to enterprises, but specific pricing and launch timeline have not been disclosed. He also mentioned that Meta's proprietary infrastructure, security systems, and data centers provide Muse with a competitive advantage that is difficult for rivals to replicate.
Report: The Trump administration plans to remove some tariffs on Canadian goods to boost the midterm elections
According to media reports, the Trump administration plans to exempt certain Canadian agricultural and forestry products from the 50% tariff, with an announcement as early as this Friday. To maintain the overall scale of tariffs, this tax reduction may be offset by imposing additional tariffs on other Canadian goods. The move is mainly intended to help Maine Senator Susan Collins retain her seat in the midterm elections, while it could also benefit other Republican candidates in trade-dependent states.
VWO ETF Closes Flat
IWF ETF Falls 0.4%
